Jasmine Singh Sukumar
Department of Breast Medical Oncology, Division of Cancer Medicine
About Jasmine Singh Sukumar
In the News
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Assistant Professor, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2016 | University of Missouri-Kansas City, Kansas City, Missouri, US, MD |
Postgraduate Training
| 2021-2022 | Postdoctoral Fellow, The Ohio State University and James Comprehensive Cancer Center, Columbus, Ohio |
| 2020-2021 | Clinical Fellowship, Breast Cancer Fellowship, The Ohio State University and James Comprehensive Cancer Center, Columbus, Ohio |
| 2019-2021 | Clinical Fellowship, Medical Oncology, The Ohio State University and James Comprehensive Cancer Center, Columbus, Ohio |
| 2016-2019 | Clinical Residency, Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, Texas |
Licenses & Certifications
| 2022 | Texas Medical License |
| 2021 | Medical Oncology |
| 2019 | ABIM Internal Medicine |
Experience & Service
Other Professional Positions
Member, Houston Nutrition and Obesity Research Center (H-NORC), Houston, TX, 2023 - Present
Member, Translational Breast Cancer Research Consortium (TBCRC) PROs working group, 2022 - Present
Member, Alliance for Clinical Trials in Oncology Symptom Intervention Committee, 2021 - Present
Member, Research Partner for GRASP (Guiding Researchers and Advocates to Scientific Partnerships), 2021 - Present
Institutional Committee Activities
Member, MD Anderson Advanced Breast Cancer (ABC) Program Advisory Committee, 2025 - Present
Committee Member, ASCO Guideline Panel Member, 2024 - Present
Member, MD Anderson Obesity Screening and Management Workgroup, 2023 - Present
Member, MD Anderson Survivorship and Database Research Advisory Workgroup, 2022 - Present
Member, MD Anderson Breast Medical Oncology Survivorship and Database Working Group, 2022 - Present
Honors & Awards
| 2024 | MD Anderson Cancer Center Institutional Research Grant |
| 2024 | The MD Anderson Center for Energy Balance in Cancer Prevention and Survivorship Supplemental Funding Award, MD Anderson |
| 2024 | The Robert A. Winn Diversity in Clinical Trials: Career Development Award |
| 2022 - 2024 | ASCO Conquer Cancer Young Investigator Award, ASCO |
| 2021 - 2022 | Transdisciplinary Research in Energetics and Cancer (TREC) Training Workshop, NIH |
| 2021 - 2022 | Pelotonia Post Doctoral Fellowship Award, The Ohio State University |
| 2021 - 2024 | Alliance Cancer Control Program Pilot Project Award |
| 2020 - 2021 | FDA-AACR Oncology Educational Fellowship, FDA-AACR |
| 2017 | Foster Fellow Research Grant, UT Southwestern Medical Center |
| 2013 | Sarah Morrison Student Research Grant, University of Missouri Kansas City |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2024. Energy Balance and Anti-tumor Immunity in Triple Negative Breast Cancer. Conference. MD Anderson Cancer Center. Houston, TX, US.
- 2023. Association Between Body Composition and Clinical Outcomes with Immune Checkpoint Inhibitors in Triple Negative Breast Cancer. Conference. MD Anderson Cancer Center. Houston, TX, US.
- 2023. Immune-related adverse effects in triple negative breast cancer: real-world patterns and clinic predictors of toxicity. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2023. Targeting Lifestyle Interventions and Body Composition in Advanced Breast Cancer” at the Advanced Breast Cancer Program Webinar. ABCs of Healthy Living in Challenging Times. Houston, TX, US.
Regional Presentations
- 2023. Targeting Obesity for Risk Reduction in Breast Cancer Survivorship. Conference. MD Anderson Cancer Center, US.
- 2022. Real World Treatment Patterns of Adjuvant Endocrine Therapy and Ovarian Suppression in Premenopausal HR+/HER2+ Breast Cancer. Poster. SABCS. San Antonio, TX, US.
National Presentations
- 2025. Retrospective Study Results: “GLP1 Receptor Agonists in Breast Cancer Survivors: Weight Loss and Patient Outcomes”. Conference. Alliance for Clinical Trials in Oncology Spring Meeting (Prevention Committee). Chicago, IL, US.
- 2025. “GLP-1 Receptor Agonists in Obesity and Cancer Control: Emerging Therapeutic Insights”. Invited. Population Sciences Working Group (PSWG) Town Hall; ("The Weight of the Matter: Obesity Drugs, Cancer, and Population Health" ). Chicago, IL, US.
- 2025. Ukraine Clinical Oncology Project ECHO (U-COPE). Invited. “Managing side-effects of hormone-blocking treatment”. Houston, TX, US.
- 2023. "Pilot Study Results: Episodic Future Thinking: A Behavioral Intervention to Promote Weight Loss in Breast Cancer Survivors”. Conference. Alliance for Clinical Trials in Oncology Fall Meeting. Chicago, IL, US.
- 2022. Episodic Future Thinking: A Behavioral Intervention to Promote Weight Loss in Breast Cancer Survivors. Conference. ASCO Annual Meeting. Chicago, IL, US.
- 2022. Delay Discounting as a Potential Therapeutic Target for Weight Loss in Breast Cancer Survivors. Conference. MASCC Annual Meeting, US.
- 2022. “Changing Behavior” Session at the Transdisciplinary Research. Conference. Energetics and Cancer (TREC) 2022 workshop, CT, US.
- 2021. Patient preferences and treatment adherence to adjuvant ovarian suppression among premenopausal women with hormone receptor positive breast cancer. Conference. Annual NCCN Conference, US.
- 2017. Inhuman activity and pharmacology of homemade silver nanoparticles in highly refractory metastatic head and neck squamous cell cancer. Conference. ASCO Annual Meeting. Chicago, IL, US.
- 2017. In-human activity and pharmacology of homemade silver nanoparticles in highly refractory metastatic head and neck squamous cell cancer. Conference. UTSW Seldin Research Symposium. Dallas, TX, US.
Grant & Contract Support
| Date: | 2025 - 2027 |
| Title: | NIH K12, BIRCHW (Building Interdisciplinary Research Careers in Women’s Health Program) |
| Funding Source: | UTMB BIRCHW Program, NIH |
| Role: | PI |
| Date: | 2025 - 2026 |
| Title: | Development of lifestyle and psychosocial intervention content for metastatic and early-stage breast cancer patients at MD Anderson Cancer Center |
| Funding Source: | With Doctor |
| Role: | Co-I |
| Date: | 2025 - 2027 |
| Title: | Randomized Trial of a Virtual, Group-based Comprehensive Lifestyle Program in Hormone Receptor Positive Metastatic Breast Cancer |
| Funding Source: | MD Anderson Cancer Center Institutional Research Grant |
| Role: | Co-I |
| Date: | 2025 - 2028 |
| Title: | ASCO Conquer Cancer – Breast Cancer Research Foundation Career Development Award (CDA) |
| Funding Source: | ASCO Conquer Cancer Foundation and Breast Cancer Research Foundation |
| Role: | PI |
| Date: | 2024 - 2026 |
| Title: | The Robert A. Winn Diversity in Clinical Trials: Career Development Award |
| Funding Source: | Bristol Myers Squibb Foundation and American Association of Cancer Research (AACR) |
| Role: | PI |
| Date: | 2024 - 2025 |
| Title: | The MD Anderson Center for Energy Balance in Cancer Prevention and Survivorship Supplemental Funding Award |
| Funding Source: | Cancer Prevention and Survivorship Supplemental Funding Award |
| Role: | PI |
| ID: | The MD Anderson Center for Energy Balance in Cancer Prevention and Survivorship Supplemental Funding Award |
| Date: | 2024 - 2026 |
| Title: | Title: Association Between BMI/Body Composition and Clinical Outcomes with Immune Checkpoint Inhibitors in Triple Negative Breast Cancer |
| Funding Source: | MD Anderson Cancer Center Institutional Research Grant |
| Role: | PI |
| Date: | 2022 - Present |
| Title: | ASCO Conquer Cancer Young Investigator Award |
| Funding Source: | American Society of Clinical Oncology (ASCO) |
| Role: | PI |
| Date: | 2021 - 2022 |
| Title: | Pelotonia Postdoctoral Fellowship Award |
| Funding Source: | The Ohio State University |
| Role: | PI |
| Date: | 2021 - Present |
| Title: | Alliance Cancer Control Program Pilot Project Award |
| Funding Source: | Alliance For Clinical Trials in Oncology |
| Role: | Co-I |
Selected Publications
Peer-Reviewed Articles
- Sukumar JS, Sardesai S, Ni A, Williams N, Johnson K, Quiroga D, Ramaswamy B, Wesolowski R, Cherian M, Stover DG, Gatti-Mays M, Pariser A, Sudheendra P, George MA, Lustberg M. Real-world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer. Cancer Med 13(12):e7317, 2024. e-Pub 2024. PMID: 38895891.
- Dennett AM, Hirko KA, Porter KJ, Loh KP, Liao Y, Yang L, Arem H, Sukumar JS, Salerno EA. Embedding lifestyle interventions into cancer care: has telehealth narrowed the equity gap?. J Natl Cancer Inst Monogr 2023(61):133-139, 2023. e-Pub 2023. PMID: 37139972.
- Stevens CJ, Liao Y, Chen M, Heredia NI, Arem H, Sukumar J, Joffe L, Schmitz KH, Mama SK. Linking social and built environmental factors to leisure-time physical activity in rural cancer survivors. J Natl Cancer Inst Monogr 2023(61):125-132, 2023. e-Pub 2023. PMID: 37139981.
- Johnson KC, Grimm M, Sukumar J, Schnell PM, Park KU, Stover DG, Jhawar SR, Gatti-Mays M, Wesolowski R, Williams N, Sardesai S, Pariser A, Sudheendra P, Tozbikian G, Ramaswamy B, Doto D, Cherian MA. Survival outcomes seen with neoadjuvant chemotherapy in the management of locally advanced inflammatory breast cancer (IBC) versus matched controls. Breast 72:103591, 2023. e-Pub 2023. PMID: 37871527.
- Sukumar JS, Vaughn JE, Tegge A, Sardesai S, Lustberg M, Stein J. Delay Discounting as a Potential Therapeutic Target for Weight Loss in Breast Cancer Survivors. Cancers (Basel) 14(5), 2022. e-Pub 2022. PMID: 35267441.
- Sukumar JS, Quiroga D, Kassem M, Grimm M, Shinde NV, Appiah L, Palettas M, Stephens J, Gatti-Mays ME, Pariser A, Cherian M, Stover DG, Williams N, Van Deusen J, Wesolowski R, Lustberg M, Ramaswamy B, Sardesai S. Patient preferences and adherence to adjuvant GnRH analogs among premenopausal women with hormone receptor positive breast cancer. Breast Cancer Res Treat 190(2):183-188, 2021. e-Pub 2021. PMID: 34498153.
- Sukumar J, Kassem M, Agnese D, Pilarski R, Ramaswamy B, Sweet K, Sardesai S. Concurrent germline BRCA1, BRCA2, and CHEK2 pathogenic variants in hereditary breast cancer: a case series. Breast Cancer Res Treat 186(2):569-575, 2021. e-Pub 2021. PMID: 33507482.
- Sardesai S, Sukumar J, Kassem M, Palettas M, Stephens J, Morgan E, Addison D, Baliga R, Stover DG, VanDeusen J, Williams N, Cherian M, Lustberg M, Wesolowski R, Ramaswamy B. Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer. Cardiooncology 6(1):26, 2020. e-Pub 2020. PMID: 33292843.
- Sukumar JS, Sukumar S, Purohit D, Welch BJ, Balani J, Yan S, Hathiramani SS. Activating BRAF mutation in sclerosing mucoepidermoid carcinoma with eosinophilia of the thyroid gland: two case reports and review of the literature. J Med Case Rep 13(1):385, 2019. e-Pub 2019. PMID: 31882020.
- Singh J, Moore W, Fattah F, Jiang X, Zheng J, Kurian P, Beg MS, Khan SA. Activity and pharmacology of homemade silver nanoparticles in refractory metastatic head and neck squamous cell cancer. Head Neck 41(1):E11-E16, 2019. e-Pub 2019. PMID: 30537286.
- Sukumar, JS, Moore, W, Khan, S. Therapy with Tyrosine Kinase Inhibitor Lenvatinib in Radioactive Iodine Naive Advanced Differentiated Thyroid Cancer. International Journal of Endocrine Oncology 6(4), 2019. e-Pub 2019.
- Singh J, Merrill ED, Sandesara PB, Schoeneberg L, Dai H, Raghuveer G. Vitamin D, Low-Grade Inflammation and Cardiovascular Risk in Young Children: A Pilot Study. Pediatr Cardiol 36(7):1338-43, 2015. e-Pub 2015. PMID: 25832850.
- Jayan A, Sukumar JS, Fangman B, Patel T, Raghavendra A, Liu D, Rauch R, Basen-Engquist K, Tripathy D, Barcenas C. Real-World Immune-related Adverse Effects in Patients with Early Triple Negative Breast Cancer who Received Pembrolizumab. JCO Oncology Practice. PMID: 39388649.
Review Articles
- Rahman N, Sukumar JS, Lustberg M. Living with Neuropathy After Cancer. Annals of Palliative Medicine 14(2):196-216, 2025. e-Pub 2025. PMID: 40211744.
- Sukumar J, Gast K, Quiroga D, Lustberg M, Williams N. Triple-negative breast cancer: promising prognostic biomarkers currently in development. Expert Rev Anticancer Ther 21(2):135-148, 2021. e-Pub 2021. PMID: 33198517.
Other Articles
- Sukumar J, Chavez Mac Gregor M POSITIVE: Pregnancy after breast cancer should be supported for many, but not all. NEJM Group Clinical Updates, 2023.
Abstracts
- Sukumar J, Sardesai S, Ni A, Williams N, Ramaswamy B, Wesolowski R, Cherian M, Stover D, Gatti-Mays M, Pariser A, Sudheendra P, George M, Lustberg M. Real World Treatment Patterns of Adjuvant Endocrine Therapy and Ovarian Suppression in Premenopausal HR+/HER2+ Breast Cancer, 2022. e-Pub 2022.
- Sukumar J, Tegge A, Sardesai S, Lustberg M, Stein J, Vaughn J. Delay Discounting as a Potential Therapeutic Target for Weight Loss in Breast Cancer Survivors, 2022. e-Pub 2022.
- Singh J, Fattah F, Burks T, Zheng J, Jiang X, Kurian P, Saleem S, Pearson J, Khan SA. Inhuman activity and pharmacology of homemade silver nanoparticles in highly refractory metastatic head and neck squamous cell cancer 35(15 Suppl):e17533-e17533, 2017. e-Pub 2017.
- Sukumar J, Raghavendra A, Pasya S, Bassett R, Tripathy D, Barcenas C, Basen-Engquist K, Arun B. Retrospective study of GLP-1 Receptor Agonist in Breast Cancer Survivors: Weight Loss and Patient Outcomes. SABCS.
- Hundal J, Ashruf O, Basen-Engquist K, Kaelber D, Sukumar JS. Disparities in GLP-1 receptor agonist prescriptions among breast cancer survivors with type 2 diabetes. ASCO Annual Meeting.
Book Chapters
- Sukumar J, Sardesai S. "PIK3CA". In: Targeted Cancer Therapy and Immunotherapy: Breast Cancer. First. Wolters Kluwer, 2022.
- Sukumar JS, Layman R. Special Considerations in Breast Cancer. In: The MD Anderson Manual of Medical Oncology.
Patient Reviews
CV information above last modified September 11, 2025